Use of the Paradigm 722 System to Improve Glycemic Control in Adult and Adolescent Subjects With Type 1 Diabetes

Completed · Not applicable

Conditions studied: Type 1 Diabetes

In brief

The purpose of this study is to determine whether Type 1 Diabetic subjects using the Paradigm 722 System, which is a glucose sensor-augmented insulin pump, can improve glycemic control when compared to subjects using the Paradigm 715 insulin pump only.

Key facts

Study ID

NCT00211510

Run by

Medtronic MiniMed, Inc.

People needed

146

Starts

2005-06-01

Expected to finish

2007-02-01

Last updated by the study team

2017-06-12

Who can join

Age: 12 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 12 - 80 years
• Type 1 Diabetes Mellitus diagnosed at least 1 year ago
• Using insulin infusion pump for past 6 months minimum
• Performing minimum 4 blood glucose tests per day
• Agree to treat to A1c targets
• Read and understand English

You may not qualify if…

• Pregnant or planning pregnancy
• History of unresolved tape allergy or skin conditions

Where it is running

• Children's Hospital of Los Angeles — Los Angeles, California, United States
• Stanford University — Stanford, California, United States
• Atlanta Diabetes Associates — Atlanta, Georgia, United States
• Joslin Diabetes Center — Boston, Massachusetts, United States
• The Endocrine Group — Albany, New York, United States
• Diabetes and Glandular Diabetes Research Associates — San Antonio, Texas, United States
• University of Washington — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.